SRX Global to acquire CERo Therapeutics unit from CERo Therapeutics Holdings
SRX Global will buy all shares of CERo Therapeutics, paying $1 million in SRX common stock priced off the lower of the prior close or 20-day VWAP and cancelling a Consolidated Senior Secured Promissory Note up to $11,666,108.77; outstanding principal was $8,249,643.77. Assumed liabilities are about $1.56 million, and S